Supplementary Material for: Monotherapy of PD-1 inhibitor camrelizumab reverses advanced lung squamous cell carcinoma with low PD-1 expression: a case report

Introduction: Chemotherapy plus immunotherapy is the standard treatment worldwide for advanced lung squamous cell carcinoma with high programed cell death protein-1 (PD-1) expression. The use of immunotherapy alone against advanced lung squamous cell carcinoma is rarely reported and data on PD-1 inhibitor camrelizumab is missing. We report the first case of camrelizumab monotherapy, which can be a reference for the clinical applications of camrelizumab in a wider context. Case Presentation: We herein present a 69-year-old male case of advanced squamous cell carcinoma with low PD-1 expression, in which camrelizumab monotherapy was administered every 3 weeks. Camrelizumab monotherapy reversed advanced lung squamous cell carcinoma without recurrence or obvious side effects during 26 months of follow-up. The patient is alive and in good conditions to date, thus progression-free survival (PFS) and overall survival (OS) are not determined. Conclusion: This case report provides evidence of the efficacy of camrelizumab monotherapy, and highlight the feasibility of camrelizumab alone against advanced lung squamous cell carcinoma when chemotherapy is not applicable.

引言：对于程序性死亡蛋白1（programed cell death protein-1, PD-1）高表达的晚期肺鳞状细胞癌，化疗联合免疫治疗是全球范围内的标准治疗方案。目前针对晚期肺鳞状细胞癌的单纯免疫治疗方案鲜有报道，且尚无PD-1抑制剂卡瑞利珠单抗（camrelizumab）的相关临床数据。本研究报道首例采用卡瑞利珠单抗单药治疗的病例，可为卡瑞利珠单抗的更广范围临床应用提供参考依据。
病例报告：本文介绍1例69岁男性晚期肺鳞状细胞癌患者，该患者肿瘤程序性死亡蛋白1表达水平较低，予以每3周1次的卡瑞利珠单抗单药治疗。经26个月随访，卡瑞利珠单抗单药治疗逆转了晚期肺鳞状细胞癌病情，随访期间未出现复发或明显不良反应。截至目前患者仍存活且状况良好，因此无进展生存期（progression-free survival, PFS）与总生存期（overall survival, OS）尚未明确。
结论：本病例报告证实了卡瑞利珠单抗单药治疗的有效性，同时凸显了当无法开展化疗时，采用卡瑞利珠单抗单药治疗晚期肺鳞状细胞癌的可行性。